Value of Breast Cancer Molecular Subtyping Documented by Independent Study Comparing Genomic Tests at ASCO 2014 Meeting
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, June 10, 2014 – Read More
African-American Women More Likely to Be Diagnosed with Higher Risk Breast Cancer
Washington, D.C., June 9, 2014 – A research study led Read More
Multiple Studies on Agendia’s MammaPrint and BluePrint Tests to Be Featured at ASCO Annual Meeting
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, May 22, 2014– New Read More
Molecular Subtyping with Agendia Tests Can Provide Better Guidance for Breast Cancer Treatment, New Research Reports
Presentations to American Society of Breast Surgeons Detail Clinical Insights Read More
Agendia Announces New Agreement with Daiichi Sankyo to Support Oncology Drug Development
Companies Will Apply Agendia Oncology Biomarker Expertise to Daiichi Sankyo Read More
Agendia Announces New Data at European Breast Cancer Conference that Further Supports Use of MammaPrint and BluePrint Tests
Presentation Shows MammaPrint Can Accurately Stratify Recurrence Risk up to Read More
Agendia Co-Founder Awarded EU Prize for Women Innovators
Laura van ‘t Veer, Ph.D., Honored as Inventor of MammaPrint Read More
Agendia Test for Molecular Subtyping of Breast Cancer Shown to Better Identify Risk of Disease Recurrence
Scientific Poster and Symposium at Miami Breast Cancer Conference Demonstrate Value Read More
Agendia Announces Upcoming Presentation of New Breast Cancer Data on Molecular Subtyping
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, February 27, 2014– A Read More
Published Study Validates Agendia’s MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome
Researchers Conclude Molecular Test Is Able to Differentiate High and Read More
